Krakow, Poland, August 6, 2015 / B3C newswire / -- Selvita, a global integrated drug discovery partner for the pharmaceutical and biotechnology industry, has been intensively expanding its operations. The total employment at Selvita increased to 261 people, including 86 PhDs in August.
The period of 2014-2015 marks a significant increase for Selvita in terms of revenue and operations, both in its drug discovery outsourcing segment as well in the internal pipeline.
The company has recently signed several large and long-term services contracts in the area of medicinal and analytical chemistry with some of the most renowned pharma companies. Selvita has also been successively expanding its capabilities in terms of proteomics, which has effected in establishing new collaborations also in this area.
The employment has been increasing accordingly, from 173 people in 2013, to 230 at the end of 2014.
Selvita is continuously investing in new laboratory infrastructure and highly qualified scientific staff, aiming to provide best quality integrated drug discovery services to pharmaceutical and biotechnology companies.
The company will publish its results for H1 2015 on August 13, 2015.
About Selvita
Selvita is a drug discovery company founded in 2007 in Krakow, Poland. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical research. Currently Selvita employs over 261 scientists, including 86 PhDs, with extensive experience in area of life sciences. Selvita's laboratories possess the GLP and GMP certification. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita offices are located in Cambridge, MA, San Bruno, CA, Cambridge, UK and Krakow, Poland. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
Contact
Natalia Baranowska
This email address is being protected from spambots. You need JavaScript enabled to view it.
+48 784 069 418